Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF - 16/06/19
, A John Camm b, Jean-Pierre Bassand c, d, Pantep Angchaisuksiri e, Frank Cools f, Ramon Corbalan g, Harry Gibbs h, Barry Jacobson i, Yukihiro Koretsune j, Lorenzo G Mantovani k, Frank Misselwitz l, Elizaveta Panchenko m, Hany Ibrahim Ragy n, Janina Stepinska o, Alexander GG Turpie p, Jitendra PS Sawhney q, Jan Steffel r, Toon Wei Lim s, Karen S Pieper d, t, Saverio Virdone d, Freek WA Verheugt u, Ajay K Kakkar d, vfor the GARFIELD-AF Investigators1
Abstract |
Introduction |
A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with newly diagnosed atrial fibrillation during an era when non–vitamin K antagonist oral anticoagulants (NOACs) were becoming more widely adopted. In these analyses, the key factors which determined the choice between NOACs and vitamin K antagonists (VKAs) are explored.
Methods |
Logistic least absolute shrinkage and selection operator regression determined predictors of NOAC and VKA use. Data were collected from 24,137 patients who were initiated on AC ± antiplatelet (AP) therapy (NOAC [51.4%] or VKA [48.6%]) between April 2013 and August 2016.
Results |
The most significant predictors of AC therapy were country, enrolment year, care setting at diagnosis, AF type, concomitant AP, and kidney disease. Patients enrolled in emergency care or in the outpatient setting were more likely to receive a NOAC than those enrolled in hospital (OR 1.16 [95% CI: 1.04-1.30], OR: 1.15 [95% CI: 1.05-1.25], respectively). NOAC prescribing seemed to be favored in lower-risk groups, namely, patients with paroxysmal AF, normotensive patients, and those with moderate alcohol consumption, but also the elderly and patients with acute coronary syndrome. By contrast, VKAs were preferentially used in patients with permanent AF, moderate to severe kidney disease, heart failure, vascular disease, and diabetes and with concomitant AP.
Conclusion |
GARFIELD-AF data highlight marked heterogeneity in stroke prevention strategies globally. Physicians are adopting an individualized approach to stroke prevention where NOACs are favored in patients with a lower stroke risk but also in the elderly and patients with acute coronary syndrome.
Le texte complet de cet article est disponible en PDF.Plan
| Clinical Trial Registration: URL: www.clinicaltrials.gov. Unique identifier: NCT01090362. |
|
| Funding: This work was supported by an unrestricted research grant from Bayer AG (Berlin, Germany) to the Thrombosis Research Institute (London, UK), which sponsors the GARFIELD-AF registry. The funding source had no involvement in the data collection, data analysis, or data interpretation. |
Vol 213
P. 35-46 - juillet 2019 Retour au numéro
Article précédent
- Right ventricular function in patients with pulmonary regurgitation with versus without tetralogy of Fallot
- Guillermo Larios, Deane Yim, Andreea Dragulescu, Luc Mertens, Lars Grosse-Wortmann, Mark K. Friedberg
- Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program
- J. Antonio Gutierrez, Deepak L. Bhatt, Subhash Banerjee, Thomas J. Glorioso, Kevin P. Josey, Rajesh V. Swaminathan, Thomas M. Maddox, Ehrin J. Armstrong, Claire Duvernoy, Stephen W. Waldo, Sunil V. Rao
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?